Overview High Dose Trial in COPD Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD. Phase: Phase 2 Details Lead Sponsor: Boehringer IngelheimTreatments: Tiotropium Bromide